Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro


Aras Y. , Erguven M., Aktas E. , Yazihan N., Bilir A.

NEUROLOGICAL RESEARCH, cilt.38, sa.9, ss.766-774, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Konu: 9
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1080/01616412.2016.1203096
  • Dergi Adı: NEUROLOGICAL RESEARCH
  • Sayfa Sayıları: ss.766-774

Özet

Objectives: Glioblastoma (GBM), the most common primary tumour of the central nervous system, is characterised by a high malignancy and poor prognosis. The aims of this study were to investigate whether the combination of imatinib mesylate (IM) and lithium chloride (LiCl) exhibited a synergistic effect in treatment and to determine whether midkine (MK) affected the fate of this treatment in vitro.